Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AC Immune ACI-24.060 Was Generally Safe And Well Tolerated In Individuals With Down Syndrome With No Serious Adverse Events Related To The Study Drug

Author: Benzinga Newsdesk | December 10, 2024 08:15am

No cases of amyloid-related imaging abnormalities observed in this study population. Based upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome.
 

Posted In: ACIU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist